KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Interest Expenses (2017 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Interest Expenses for 17 consecutive years, with $12.9 million as the latest value for Q1 2026.

  • For Q1 2026, Interest Expenses rose 48.28% year-over-year to $12.9 million; the TTM value through Mar 2026 reached $48.0 million, changed 0.42%, while the annual FY2025 figure was $43.8 million, 20.65% down from the prior year.
  • Interest Expenses hit $12.9 million in Q1 2026 for Regeneron Pharmaceuticals, up from $12.2 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $19.3 million in Q3 2025 and bottomed at $3.6 million in Q2 2025.
  • Average Interest Expenses over 5 years is $14.4 million, with a median of $14.8 million recorded in 2024.
  • Year-over-year, Interest Expenses plummeted 75.68% in 2025 and then surged 48.28% in 2026.
  • Regeneron Pharmaceuticals' Interest Expenses stood at $17.4 million in 2022, then increased by 5.17% to $18.3 million in 2023, then plummeted by 42.62% to $10.5 million in 2024, then grew by 16.19% to $12.2 million in 2025, then increased by 5.74% to $12.9 million in 2026.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $12.9 million, $12.2 million, and $19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.